Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Immunotherapy maintenance in acute non-lymphocytic leukaemia.

Paton CM, Bishop JF, Mathews JD, Whiteside MG.

Aust N Z J Med. 1982 Dec;12(6):583-9.

PMID:
6762195
2.

A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.

Hayat M, Jehn U, Willemze R, Haanen C, Zittoun R, Monconduit M, Lowenberg B, Stryckmans P, Peetermans M, De Cataldo F, et al.

Cancer. 1986 Aug 1;58(3):617-23.

3.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
4.

A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

Vogler WR, Winton EF, Gordon DS, Raney MR, Go B, Meyer L.

Blood. 1984 May;63(5):1039-45.

5.

[Non-lymphoblastic acute leukaemia: maintenance therapy by trial of a combination of chemo- and immunotherapy (author's transl)].

S├ębahoun G, Gastaut JA, Imbert-Xeridat C, Favre R, Carcassonne Y.

Nouv Presse Med. 1979 Feb 24;8(9):663-5. French.

PMID:
377219
6.

Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.

Zuhrie SR, Harris R, Freeman CB, MacIver JE, Geary CG, Delamore IW, Tooth JA.

Br J Cancer. 1980 Mar;41(3):372-7.

7.

Treatment of acute myelogenous leukemia: influence of three induction regimens and maintenance with chemotherapy or BCG immunotherapy.

Omura GA, Vogler WR, Lefante J, Silberman H, Knospe W, Gordon D, Jarrell R.

Cancer. 1982 Apr 15;49(8):1530-6.

8.
10.

The immunotherapy of acute myelogenous leukaemia using intravenous BCG.

Whittaker JA, Slater AJ.

Br J Haematol. 1977 Feb;35(2):263-73.

PMID:
322696
11.

Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials.

Whittaker JA, Bailey-Wood R, Hutchins S.

Br J Haematol. 1980 Jul;45(3):389-400.

PMID:
7000149
12.

BCG therapy in acute non lymphoid leukaemias.

Vuvan H, Fiere D, Doillon M, Martin C, Coiffier B, Felman P, Bryon PA, Favre-Gilly J, Revol L.

Scand J Haematol. 1978 Jul;21(1):40-6.

PMID:
358371
13.

Management of adult acute myelogenous leukaemia.

Crowther D, Powles RL, Bateman CJ, Beard ME, Gauci CL, Wrigley PF, Malpas JS, Fairley GH, Scott RB.

Br Med J. 1973 Jan 20;1(5846):131-7.

14.
15.

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.

Harris R, Zuhrie SR, Freeman CB, Taylor GM, MacIver JE, Geary CG, Delamore IW, Hull PJ, Tooth JA.

Br J Cancer. 1978 Feb;37(2):282-8.

16.

Chemoimmunotherapy of adult acute leukemia.

McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ.

Cancer. 1981 Mar 15;47(6):1256-61.

17.

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M.

Blood. 1996 Oct 15;88(8):2841-51.

18.

Long-term follow-up results of adult patients with acute lymphocytic leukemia or lymphoblastic lymphoma treated with short-term, alternating non-cross-resistant chemotherapy: Japan Clinical Oncology Group Study 8702. Lymphoma Study Group.

Kobayashi T, Tobinai K, Shimoyama M, Mikuni C, Konda S, Kozuru M, Araki K, Sai T, Fukuhara S, Matsumoto M, Aoki I, Deura K, Oyama A, Hotta T, Abe T, Toki H, Nagai M, Fukuda H, Niimi M, Yamaguchi N, Tajima K, Shirakawa S.

Jpn J Clin Oncol. 1999 Jul;29(7):340-8.

PMID:
10470659
19.

Chemoimmunotherapy for maintenance in acute myeloblastic leukemia.

Whiteside MG, Cauchi MN, Paton C, Stone J.

Cancer. 1976 Oct;38(4):1581-6.

20.

[Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen].

Takahashi I, Uchida K, Ohmoto E, Endo H, Oda Y, Fujimoto S, Hara M, Takaoka K, Watanabe S, Lai M, Kohi F, Kitajima K, Kimura I, Sanada H, Tokioka M, Adachi T, Yorimitsu S.

Gan To Kagaku Ryoho. 1982 Jul;9(6):1091-6. Japanese.

PMID:
6964045

Supplemental Content

Support Center